TWD 16.15
(0.31%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 162.48 Million TWD | 19.95% |
2022 | 135.46 Million TWD | -19.81% |
2021 | 168.93 Million TWD | 84.01% |
2020 | 91.81 Million TWD | -3.85% |
2019 | 95.48 Million TWD | -11.16% |
2018 | 107.48 Million TWD | 99.06% |
2017 | 53.99 Million TWD | 115.8% |
2016 | 25.02 Million TWD | 19.27% |
2015 | 20.97 Million TWD | -76.88% |
2014 | 90.73 Million TWD | -37.42% |
2013 | 144.98 Million TWD | -18.41% |
2012 | 177.71 Million TWD | 14.58% |
2011 | 155.09 Million TWD | 43.73% |
2010 | 107.9 Million TWD | 8.78% |
2009 | 99.19 Million TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 32.58 Million TWD | -30.07% |
2024 Q2 | 44.12 Million TWD | 35.4% |
2024 Q3 | 39.81 Million TWD | -9.76% |
2023 Q3 | 43.51 Million TWD | 10.42% |
2023 Q4 | 46.6 Million TWD | 7.1% |
2023 FY | 162.48 Million TWD | 19.95% |
2023 Q1 | 32.96 Million TWD | -2.52% |
2023 Q2 | 39.4 Million TWD | 19.56% |
2022 Q2 | 32.89 Million TWD | -5.92% |
2022 Q3 | 33.79 Million TWD | 2.75% |
2022 Q4 | 33.81 Million TWD | 0.05% |
2022 Q1 | 34.96 Million TWD | -13.94% |
2022 FY | 135.46 Million TWD | -19.81% |
2021 Q2 | 55.21 Million TWD | 119.32% |
2021 Q4 | 40.62 Million TWD | -15.25% |
2021 FY | 168.93 Million TWD | 84.01% |
2021 Q1 | 25.17 Million TWD | -20.77% |
2021 Q3 | 47.93 Million TWD | -13.19% |
2020 Q3 | 23.61 Million TWD | 2.82% |
2020 Q2 | 22.96 Million TWD | 70.62% |
2020 Q1 | 13.46 Million TWD | -4.71% |
2020 Q4 | 31.77 Million TWD | 34.56% |
2020 FY | 91.81 Million TWD | -3.85% |
2019 Q3 | 17.49 Million TWD | -46.74% |
2019 FY | 95.48 Million TWD | -11.16% |
2019 Q1 | 31.02 Million TWD | 28.79% |
2019 Q2 | 32.84 Million TWD | 5.89% |
2019 Q4 | 14.12 Million TWD | -19.26% |
2018 Q2 | 28.45 Million TWD | -3.68% |
2018 FY | 107.48 Million TWD | 99.06% |
2018 Q4 | 24.08 Million TWD | -5.19% |
2018 Q3 | 25.4 Million TWD | -10.72% |
2018 Q1 | 29.54 Million TWD | 79.35% |
2017 Q3 | 18.82 Million TWD | 67.11% |
2017 FY | 53.99 Million TWD | 115.8% |
2017 Q2 | 11.26 Million TWD | 51.64% |
2017 Q4 | 16.47 Million TWD | -12.52% |
2017 Q1 | 7.43 Million TWD | -18.32% |
2016 Q1 | 2.81 Million TWD | -49.75% |
2016 FY | 25.02 Million TWD | 19.27% |
2016 Q3 | 6.95 Million TWD | 12.84% |
2016 Q4 | 9.09 Million TWD | 30.87% |
2016 Q2 | 6.16 Million TWD | 118.98% |
2015 Q1 | 4.77 Million TWD | -33.26% |
2015 Q2 | 5.21 Million TWD | 9.21% |
2015 Q3 | 5.38 Million TWD | 3.3% |
2015 Q4 | 5.59 Million TWD | 3.9% |
2015 FY | 20.97 Million TWD | -76.88% |
2014 Q4 | 7.15 Million TWD | -74.62% |
2014 Q2 | 27.79 Million TWD | 0.74% |
2014 FY | 90.73 Million TWD | -37.42% |
2014 Q1 | 27.59 Million TWD | -1.25% |
2014 Q3 | 28.19 Million TWD | 1.43% |
2013 Q3 | 26.15 Million TWD | -44.06% |
2013 Q1 | 44.13 Million TWD | -9.01% |
2013 FY | 144.98 Million TWD | -18.41% |
2013 Q4 | 27.94 Million TWD | 6.81% |
2013 Q2 | 46.76 Million TWD | 5.96% |
2012 Q3 | 47.77 Million TWD | -12.21% |
2012 Q2 | 54.41 Million TWD | 101.32% |
2012 Q1 | 27.02 Million TWD | -50.73% |
2012 Q4 | 48.49 Million TWD | 1.52% |
2012 FY | 177.71 Million TWD | 14.58% |
2011 Q1 | 23.45 Million TWD | -53.02% |
2011 FY | 155.09 Million TWD | 43.73% |
2011 Q4 | 54.86 Million TWD | 42.62% |
2011 Q3 | 38.46 Million TWD | 0.42% |
2011 Q2 | 38.3 Million TWD | 63.34% |
2010 FY | 107.9 Million TWD | 8.78% |
2010 Q4 | 49.91 Million TWD | 85.72% |
2010 Q1 | 5.35 Million TWD | 0.0% |
2010 Q2 | 25.75 Million TWD | 381.0% |
2010 Q3 | 26.87 Million TWD | 4.37% |
2009 FY | 99.19 Million TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Grape King Bio Ltd | 10.63 Billion TWD | 98.472% |
Standard Chem & Pharm CO., LTD. | 6.23 Billion TWD | 97.396% |
Maywufa Company Ltd. | 1.3 Billion TWD | 87.508% |
ScinoPharm Taiwan, Ltd. | 3.18 Billion TWD | 94.9% |
Lotus Pharmaceutical Co., Ltd. | 16.95 Billion TWD | 99.042% |
LIWANLI Innovation Co., Ltd. | 38.88 Million TWD | -317.849% |
YungShin Global Holding Corporation | 7.02 Billion TWD | 97.688% |
SCI Pharmtech, Inc. | 1.2 Billion TWD | 86.506% |
Formosa Laboratories, Inc. | 4.36 Billion TWD | 96.274% |
PharmaEssentia Corporation | 5.1 Billion TWD | 96.817% |
Bora Pharmaceuticals Co., LTD. | 14.2 Billion TWD | 98.856% |